Navigation Links
KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants
Date:10/11/2007

ward- looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (6) reliance on key strategic alliances; (7) the availability of raw materials; (8) the regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of predicting international regulatory approval, including timing; (11) the difficulty of predicting the pattern of inventory movements by the Company's customers; (12) the impact of competitive response to the Company's sales, marketing and strategic efforts; (13) risks that the Company may not ultimately prevail in litigation; (14) the proposed restatement of the Company's financial statements for fiscal periods from 1996 through 2006 and for the quarter ended June 30, 2006, as well as completion of the Company's financial statements for the second, third and fourth quarters of fiscal 2007 and for the full fiscal year
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008).../ -- Due to the urgent need to disseminate authori...ch and clinical care, publisher Mary Ann Liebert...ll archival online issues of the company,s AIDS jo...ld AIDS Day. Free online access is available for .../apc ) and AIDS Research and Human Retroviruses ...
(Date:12/1/2008)...Call/ -- Senetek PLC,(OTC Bulletin Board: SNKTY),...nt of technologies that target the science of heal..., specialists in the fields of strategic,developm...fices in Zurich,Bern and Geneva has published a ...rch Report, available in the "Investors" section o...
(Date:12/1/2008)...l disaster relief campaign , , WASHINGTON, ... Cross is asking people across the nation to help .... This holiday season push will put the final touc...ign for Disaster Relief. Already, the campaign has...tember, and the Red Cross hopes to meet its target...
(Date:12/1/2008)...-- Medication therapy management,(MTM) provider P...nals to its,advisory board. , New members ...y, M.D.;,Michael Burcham; and Kevin Hutchinson. ...s helped PharmMD launch and hone its MTM services,...suse, overuse and abuse. MTM is proven,to reduce...
Breaking Medicine News(10 mins):Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 2Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 3Health News:PharmMD Expands Advisory Board 2
...ays and after many comfortable winter evenings, ma...arly// on their hips, thighs and buttocks. But on...panic, said Isabelle Keller of the German Society ...hen people return to their usual nutritional habit...
...latest report published in Archives of Otolaryngol...attributed// to psychiatric or neurologic conditio...n and women who had suffered dizziness for an exte...n the age group of 15 to 89. It was found that 339...
...ay be smiling. Researchers have given their opinio...sarian operations//, those decided solely upon by ...cording to their results published in the Canadian... encountered by a woman who opts for a C-section, ...
...ons has determined that by modifying a classic lig... as baseball players//, to their prior level of co...ial collateral ligament (MCL), which links and sta...rm where they meet at the elbow. Less traumatic ...
Other Medicine News:Health News:Permanent Weight Loss Requires Transition to Healthy Eating 2Health News:Modified Ligament Surgery Improves Outcomes Players, Athletes 2Health News:Modified Ligament Surgery Improves Outcomes Players, Athletes 3
(Date:12/1/2008)...y switch that, if turned off, causes lymphatic end...e their identity and become more like blood endoth...ewswire-USNewswire/ -- Scientists at St. Jude Chi...ertain differentiated cell type is so ready to cha...ression of a gene called Prox1 to dissuade it. ...
(Date:12/1/2008)...Call/ -- Genaera Corporation (Nasdaq: GENR ) to... study MSI-1436C-102 (Study 102), the multiple asc...436) in overweight and obese type 2 diabetics. MSI...type 2 diabetes and obesity which works centrally ...thways through the highly selective inhibition of ...
(Date:12/1/2008)...ber 9 at 11:00 am ET to Discuss Phase 2 Study Resu...if., Dec. 1 Sunesis Ph...ceutical company focused on the development and co...y announced new data from its studies of voreloxin... during the 50th American Society of Hematology (A...
(Date:12/1/2008)...al Incorporated (Nasdaq: VICL ) announced today ...om Merck & Co., Inc. based on Merck,s planned ...tigational plasmid DNA (pDNA) cancer vaccine. The ...ivery technology and encodes human telomerase reve... separate license agreement. , , "The bread...
Breaking Medicine Technology:Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Vitamin D and breast cancer risk 17194 1Vitamin D and breast cancer risk 17194 2Study finds patients overestimate cancer screening history 17192 1Study finds patients overestimate cancer screening history 17192 2Woodland Park Care Center Earns Quality Respiratory Care Recognition 17190 1Woodland Park Care Center Earns Quality Respiratory Care Recognition 17190 2Huifeng Bio Pharmaceutical 28HFGB 29 Announces Participation in the 59th PHARMCHINA Expo 17188 1Huifeng Bio Pharmaceutical 28HFGB 29 Announces Participation in the 59th PHARMCHINA Expo 17188 2
...Professor Home said: , "The editorials published b...t they disregarded important pieces of data that,a...Most,significantly the editorials ignored data tha...ular death or death from any,cause." , Professor P...778-525-1736 , Terms and conditions of use apply ...
...ief within 5,minutes of dosing and is well-tolerat...arma Ltd,("Archimedes"), a European specialty phar...ata from a Phase II study of Nasalfent(r),an inno...ding a,fast, effective and convenient treatment fo... the 10th Congress of the European,Association for...
Other Medicine Technology:Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 2Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 3
Holligard protects skin from irritating stomal discharge. Holligard is flexible and durable in heat and humidity.
Inquire
Inquire
Contour I pouches are light as a feather and feature our tapered SoftFlex skin barrier for comformability, flexbility and comfort. All Contour I pouches have ComfortWear panels that keep skin cool an
Medicine Products: